Patents by Inventor Seung U. Kim
Seung U. Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240274456Abstract: A substrate planarization device according to embodiments of the present disclosure may include a peripheral coupler including a first electrostatic chuck configured to be attached to a peripheral area of a substrate, and a first elevator configured to raise and lower the first electrostatic chuck in a vertical direction within a first movable range, and a central coupler including a second electrostatic chuck configured to be attached to a central area of the substrate, and a second elevator that is configured to raise and lower the second electrostatic chuck in the vertical direction within a second movable range that is greater than the first movable range. According to the substrate planarization device, a deposition system comprising the same, and a method of operating the substrate planarization device according to embodiments of the present disclosure, the substrate can be planarized.Type: ApplicationFiled: January 17, 2024Publication date: August 15, 2024Inventors: Cheol Rae JO, Seung Ho MYOUNG, Yeong Min KIM, Yong U JEONG
-
Publication number: 20120107282Abstract: Disclosed is a method of treatment of an individual suffering from primary brain tumors (glioma and medulloblastoma) and brain metastases of extracranial cancers using human stem cells encoding therapeutic genes. The method includes giving the individual a clinically acceptable therapeutic reagent by intravascular injection of a pharmaceutical composition. The pharmaceutical composition includes neural stem cells (NSCs) genetically engineered to express a suicide gene (cytosine deaminase) and a cytokine gene (IFN-?) and a pharmaceutical carrier suitable for injection. The NSCs migrate selectively to tumor site in the brain, target tumor cells, kill tumor cells, inhibit tumor growth and thus treat the tumor.Type: ApplicationFiled: September 28, 2011Publication date: May 3, 2012Applicant: S. BIOMEDICS CO., LTD.Inventor: Seung U. Kim
-
Publication number: 20040214332Abstract: Stable clones of neural stem cells (NSCs) have been isolated from the human fetal telencephalon. In vitro, these self-renewing clones (affirmed by retroviral insertion site) can spontaneously give rise to all 3 fundamental neural cell types (neurons, oligodendrocytes, astrocytes). Following transplantation into germinal zones of the developing newborn mouse brain, they, like their rodent counterparts, can participate in aspects of normal development, including migration along well-established migratory pathways to disseminated CNS regions, differentiation into multiple developmentally- and regionally-appropriate cell types in response to microenvironmental cues, and non-disruptive, non-tumorigenic interspersion with host progenitors and their progeny. Readily genetically engineered prior to transplantation, human NSCs are capable of expressing foreign transgenes in vivo in these disseminated locations.Type: ApplicationFiled: December 15, 2003Publication date: October 28, 2004Applicants: Children's Medical Center Corporation, University of British Columbia, University of PennsylvaniaInventors: Snyder Y. Evan, John H. Wolfe, Seung U. Kim
-
Patent number: 6780641Abstract: An immortalized human cell line is provided which has the characteristics of human embryonic microglia. Such immortalized microglia cells express CD68, CD11c and MHC class I and II antigens as surface markers; have demonstrable phagocytic properties; and produce progeny continuously while maintained in culture. A method of transforming human microglial cells into an immortalized cell line is also provided. The genetically modified human microglia cells can express active substances from a selected group consisting of MIP-1&bgr;, MCP-1, IL-1&bgr;, IL-6, IL-12, and IL-15; and in the stimulated state can overexpress at lest cytokines, chemokines, and other cytotoxic and neurotoxic substances. Such immortalized microglia cells can be used for screening of compounds for diseases. These cells may be utilized for the treatment of at least Alzheimer disease, Parkinson disease, Huntington disease, amyotrophic lateral sclerosis, stroke, spinal cord injuries, ataxia, autoimmune diseases and AIDS-dementia.Type: GrantFiled: June 22, 2001Date of Patent: August 24, 2004Assignee: University of British ColumbiaInventor: Seung U. Kim
-
Patent number: 6680198Abstract: Stable clones of neural stem cells (NSCs) have been isolated from the human fetal telencephalon. In vitro, these self-renewing clones (affirmed by retroviral insertion site) can spontaneously give rise to all 3 fundamental neural cell types (neurons, oligodendrocytes, astrocytes). Following transplantation into germinal zones of the developing newborn mouse brain, they, like their rodent counterparts, can participate in aspects of normal development, including migration along well-established migratory pathways to disseminated CNS regions, differentiation into multiple developmentally- and regionally-appropriate cell types in response to microenvironmental cues, and non-disruptive, non-tumorigenic interspersion with host progenitors and their progeny. Readily genetically engineered prior to transplantation, human NSCs are capable of expressing foreign transgenes in vivo in these disseminated locations.Type: GrantFiled: September 20, 1999Date of Patent: January 20, 2004Assignees: The Children's Medical Center Corporation, University of British Columbia, University of PennsylvaniaInventors: Evan Y. Snyder, John H. Wolfe, Seung U. Kim
-
Publication number: 20030082139Abstract: An immortalized human cell line is provided which has the characteristics of human embryonic microglia. Such immortalized microglia cells express CD68, CD11c and MHC class I and II antigens as surface markers; have demonstrable phagocytic properties; and produce progeny continuously while maintained in culture. A method of transforming human microglial cells into an immortalized cell line is also provided. The genetically modified human microglia cells can express active substances from a selected group consisting of MIP-1&bgr;, MCP-1, IL-1&bgr;, IL-6, IL-12, and IL-15; and in the stimulated state can overexpress at lest cytokines, chemokines, and other cytotoxic and neurotoxic substances. Such immortalized microglia cells can be used for screening of compounds for diseases. These cells may be utilized for the treatment of at least Alzheimer disease, Parkinson disease, Huntington disease, amyotrophic lateral sclerosis, stroke, spinal cord injuries, ataxia, autoimmune diseases and AIDS-dementia.Type: ApplicationFiled: June 22, 2001Publication date: May 1, 2003Inventor: Seung U. Kim
-
Patent number: 6541255Abstract: Stable clones of neural stem cells (NSCs) have been isolated from the human fetal telencephalon. In vitro, these self-renewing clones (affirmed by retroviral insertion site) can spontaneously give rise to all 3 fundamental neural cell types (neurons, oligodendrocytes, astrocytes). Following transplantation into germinal zones of the developing newborn mouse brain, they, like their rodent counterparts, can participate in aspects of normal development, including migration along well-established migratory pathways to disseminated CNS regions, differentiation into multiple developmentally- and regionally-appropriate cell types in response to microenvironmental cues, and non-disruptive, non-tumorigenic interspersion with host progenitors and their progeny. Readily genetically engineered prior to transplantation, human NSCs are capable of expressing foreign transgenes in vivo in these disseminated locations.Type: GrantFiled: September 20, 1999Date of Patent: April 1, 2003Assignees: The Children's Medical Center Corporation, The University of British Columbia, The University of PennsylvaniaInventors: Evan Y. Snyder, John H. Wolfe, Seung U. Kim
-
Patent number: 6528306Abstract: Stable clones of neural stem cells (NSCs) have been isolated from the human fetal telencephalon. In vitro, these self-renewing clones (affirmed by retroviral insertion site) can spontaneously give rise to all 3 fundamental neural cell types (neurons, oligodendrocytes, astrocytes). Following transplantation into germinal zones of the developing newborn mouse brain, they, like their rodent counterparts, can participate in aspects of normal development, including migration along well-established migratory pathways to disseminated CNS regions, differentiation into multiple developmentally- and regionally-appropriate cell types in response to microenvironmental cues, and non-disruptive, non-tumorigenic interspersion with host progenitors and their progeny. Readily genetically engineered prior to transplantation, human NSCs are capable of expressing foreign transgenes in vivo in these disseminated locations.Type: GrantFiled: September 20, 1999Date of Patent: March 4, 2003Assignees: The Children's of Medical Center Corporation, The University of British Columbia, The University of PennsylvaniaInventors: Evan Y. Snyder, John H. Wolfe, Seung U. Kim
-
Publication number: 20020064877Abstract: An immortalized human cell line has the characteristics of human microglia. It expresses the CD 8 and CD11c antigens. The immortalized human cell line has at least three of the following attributes: CD11b (Mac1), CD68, HLA-ABC, HLA-DR, IL-1b, IL-6, IL-8, IL-12, IL-15, TGF-b, TNF-a, MIP-1a, MIP-1b, MCP-1, P2Y1R, P2Y2R. Also disclosed is a method of transforming human microglial cells into an immortalized cell line, a method of testing drugs for effects on human microglial cells and a method of treating individuals experiencing neurodegenerative disorders.Type: ApplicationFiled: May 15, 2001Publication date: May 30, 2002Inventor: Seung U. Kim
-
Patent number: 5958767Abstract: Stable clones of neural stem cells (NSCs) have been isolated from the human fetal telencephalon. In vitro, these self-renewing clones (affirmed by retroviral insertion site) can spontaneously give rise to all 3 fundamental neural cell types (neurons, oligodendrocytes, astrocytes). Following transplantation into germinal zones of the developing newborn mouse brain, they, like their rodent counterparts, can participate in aspects of normal development, including migration along well-established migratory pathways to disseminated CNS regions, differentiation into multiple developmentally- and regionally-appropriate cell types in response to microenvironmental cues, and non-disruptive, non-tumorigenic interspersion with host progenitors and their progeny. Readily genetically engineered prior to transplantation, human NSCs are capable of expressing foreign transgenes in vivo in these disseminated locations.Type: GrantFiled: August 14, 1998Date of Patent: September 28, 1999Assignee: The Children's Medical Center Corp.Inventors: Evan Y. Snyder, John H. Wolfe, Seung U. Kim